0
Precision Medicine Answers for Kids Today Act
12/30/2022, 8:18 AM
Summary of Bill HR 5989
Precision medicine is an approach to medical treatment that takes into account individual variability in genes, environment, and lifestyle for each person. This bill specifically focuses on applying precision medicine techniques to children, who often have unique medical needs that differ from adults.
The Precision Medicine Answers for Kids Today Act aims to establish a national pediatric research network that will collect and analyze data on pediatric diseases. This network will help researchers and healthcare providers better understand the underlying causes of childhood illnesses and develop more targeted and effective treatments. Additionally, the bill seeks to improve coordination and collaboration among various stakeholders in the field of pediatric precision medicine, including researchers, healthcare providers, and patient advocacy groups. By fostering partnerships and sharing data, the hope is to accelerate the development of new therapies and cures for pediatric diseases. Overall, the Precision Medicine Answers for Kids Today Act is a bipartisan effort to advance the field of pediatric precision medicine and improve outcomes for children with complex medical conditions. It represents a significant step towards personalized and effective healthcare for our nation's youngest patients.
Congressional Summary of HR 5989
Precision Medicine Answers for Kids Today Act
This bill establishes programs and requires reporting relating to Medicaid coverage of genetic and genomic testing, particularly for children.
Specifically, the bill establishes a demonstration program for up to 15 state Medicaid programs to cover genetic and genomic testing for certain individuals under the age of 21 (or a lower age, if the state chooses) and for former foster youth under the age of 26.
Additionally, the Centers for Medicare & Medicaid Services must report on overall Medicaid coverage of such services and issue guidance for states on ways to increase coverage for children; the National Academy of Medicine must study the impact of this guidance as well as the general utility of genetic and genomic testing.





